Market capitalization | $59.02m |
Enterprise Value | $58.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 45.24 |
P/S ratio (TTM) P/S ratio | 45.75 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 97.50% |
Revenue (TTM) Revenue | $1.29m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a VolitionRX forecast:
3 Analysts have issued a VolitionRX forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.29 1.29 |
98%
98%
|
|
Gross Profit | -0.06 -0.06 |
92%
92%
|
|
EBITDA | -29 -29 |
16%
16%
|
EBIT (Operating Income) EBIT | -30 -30 |
15%
15%
|
Net Profit | -30 -30 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Head office | United States |
CEO | Cameron Reynolds |
Employees | 110 |
Founded | 1998 |
Website | www.volition.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.